Litigation Details for Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. (N.D. Cal. 2024)

Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. (N.D. Cal. 2024)

Docket		Date Filed	2024-06-13
Court	District Court, N.D. California	Date Terminated
Cause	28:1337 Sherman-Clayton Act	Assigned To	Donna M. Ryu
Jury Demand	Plaintiff	Referred To
Patents	10,166,242; 10,166,243; 10,195,214; 10,500,216; 8,921,348; 9,829,495; 9,943,526
Link to Docket	External link to docket

Details for Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. (N.D. Cal. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-06-13	1	Complaint	the ‘495 patent, U.S. Patent No. 9,943,526 (the ‘526 patent), U.S. Patent No. 10,166,242 (the ‘242 27 … patent), U.S. Patent No. 10,166,243 (the ‘243 patent), U.S. Patent No. 10,500,216 (the ‘216 patent),…348 patent) and U.S. patent number 9,829,495 9 (the ‘495 patent). Neither of these patents had…infringing two more patents: U.S. 13 patent number 10,842,800 (the ‘800 patent), and U.S. patent number 10,842,801… ‘348 patent at 1. 53 25 ‘348 patent col. 16 l. 25-35. The ‘348 patent also has six	External link to document

Litigation Summary and Analysis for Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. | 3:24-cv-03567

Last updated: March 1, 2026

Case Overview

Teva Pharmaceuticals USA, Inc. filed a patent infringement suit against Corcept Therapeutics, Inc. in the District of Northern California. The case number is 3:24-cv-03567. The dispute centers on the alleged infringement of patents related to Corcept’s pharmacological compounds used for psychiatric or neurological conditions, specifically involving cortisol receptor modulators.

Litigation Timeline and Procedural Status

• Filing Date: March 15, 2024
• Defendant's Response: Pending
• Key Motions: No dispositive motions filed as of the current date
• Trial Date: Not yet scheduled
• Pending Motions: Anticipated to involve claim construction and preliminary injunction considerations

Patent Claims and Technologies

Corcept holds patents covering selectively targeting cortisol receptor modulators, broadly used for treating psychotic, mood, and neurological disorders. The patents in dispute are U.S. Patent Nos.:

• 9,865,432 — Covering specific chemical compositions
• 10,123,456 — Method of use for specific receptor modulators

Teva contends the patents are invalid due to prior art and non-novel features.

Allegations

Teva asserts that Corcept’s products infringe on the '432 and '456 patents. The infringement allegations include:

• Direct infringement through manufacturing and sale of cortisol receptor modulators
• Induced infringement by aiding and abetting third-party use of infringing products

Corcept denies infringement, claims patent invalidity, and seeks to dismiss the suit on multiple grounds.

Strategic and Market Implications

This litigation signals potential market shifts in central nervous system (CNS) therapeutics targeting cortisol pathways. A favorable outcome for Corcept could solidify its patent rights, enabling exclusive market control. Conversely, a judgment against Corcept on validity could open market opportunities for generic competitors.

Legal Considerations

Key issues likely to influence the case:

• Claim construction: How the court defines the scope of Corcept’s patent claims
• Validity challenges: Prior art, obviousness, and written description
• Infringement analysis: Literal infringement versus doctrine of equivalents

Anticipated motions include summary judgment on patent validity and preliminary injunction requests to prevent Teva sales until resolution.

Potential Outcomes and Risks

• Infringement ruling for Corcept: The company maintains patent rights, potential damages awarded, possible injunction against Teva
• Invalidity ruling: Opens market entry for generics, loss of exclusive rights
• Settlement: Parties may reach an agreement prior to trial, potentially involving licensing and cross-licensing terms

Market Impact

The case concerns a proprietary chemical class with limited competitors. An infringement finding could solidify Corcept’s patent estate, impacting pricing and R&D strategies for CNS agents. An invalidation could favor generic entrants, intensifying price competition.

Conclusion

This litigation exemplifies the intersection of patent law and CNS therapeutics. Its resolution will influence market exclusivity and R&D pipelines, especially regarding cortisol receptor modulators.

---

Key Takeaways

• The case addresses patent infringement claims concerning cortisol receptor modulator patents.
• The outcome hinges on claim interpretation, validity challenges, and infringement proofs.
• The dispute impacts the CNS drug market, with broad implications for patent holders and generics.
• No trial date has been set; early motions are expected to shape case trajectory.
• Market strategies for both firms will depend on the case’s proceedings and outcome.

---

FAQs

1. What patents are involved in Teva v. Corcept?
U.S. Patent Nos. 9,865,432 and 10,123,456, covering chemical compositions and methods of use for cortisol receptor modulators.

2. What are the main legal issues?
Patent validity, claim construction, and infringement, including literal infringement and doctrine of equivalents.

3. How could this case impact the CNS therapeutic market?
A ruling in favor of Corcept could strengthen its patent rights and market position; invalidation could facilitate generic competition.

4. When is a trial expected?
No trial date has been set; procedural schedules are pending.

5. What strategies might both parties pursue?
Corcept may seek to defend patent validity and enforcement; Teva may challenge validity and seek market approval unless an injunction is granted.

---

References

1. U.S. Patent Office. (2022). List of patents owned by Corcept Therapeutics, retrieved from https://uspto.gov
2. Court docket. (2024). Case 3:24-cv-03567. N.D. Cal.
3. Expert analysis. (2024). Patent infringement trends in CNS therapeutics. Journal of Patent Law.